Evidence map›Paper›PMID 39496848›Full record

ReviewNature reviews. Neurology2024

Parkinson disease therapy: current strategies and future research priorities.

Fabrizio Stocchi, Daniele Bravi, Aron Emmi, Angelo Antonini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Baseline peripheral inflammatory profiles predict phenoconversion in prodromal Parkinson's disease: a longitudinal cohort study.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Toward the prevention of clinically manifest Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fabrizio StocchiDepartment of Neurology, University San Raffaele, Rome, Italy. fabrizio.stocchi@sanraffaele.it.ORCID 0000-0002-5763-0033
Daniele BraviDeptartment of Neurology, Institute for Research and Medical Care, IRCCS San Raffaele, Rome, Italy.
Aron EmmiCenter for Neurodegenerative Diseases (CESNE), Department of Neuroscience, University of Padova, Padova, Italy.ORCID 0000-0002-2796-5676
Angelo AntoniniCenter for Neurodegenerative Diseases (CESNE), Department of Neuroscience, University of Padova, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson disease (PD) is the fastest growing neurological disorder globally and poses substantial management challenges owing to progressive disability, emergence of levodopa-resistant symptoms, and treatment-related complications. In this Review, we examine the current state of research into PD therapies and outline future priorities for advancing our understanding and treatment of the disease. We identify two main research priorities for the coming years: first, slowing the progression of the disease through the integration of sensitive biomarkers and targeted biological therapies, and second, enhancing existing symptomatic treatments, encompassing surgical and infusion therapies, with the goal of postponing complications and improving long-term patient management. The path towards disease modification is impeded by the multifaceted pathophysiology and diverse mechanisms underlying PD. Ongoing studies are directed at α-synuclein aggregation, complemented by efforts to address specific pathways associated with the less common genetic forms of the disease. The success of these efforts relies on establishing robust end points, incorporating technology, and identifying reliable biomarkers for early diagnosis and continuous monitoring of disease progression. In the context of symptomatic treatment, the focus should shift towards refining existing approaches and fostering the development of novel therapeutic strategies that target levodopa-resistant symptoms and clinical manifestations that substantially impair quality of life.

Indexed as

Parkinson DiseaseAntiparkinson AgentsBiomarkersBiomedical ResearchDisease ProgressionHumansAntiparkinson AgentsBiomarkers

Identifiers

PMID39496848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.